Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €101.23 EUR
Change Today +3.82 / 3.92%
Volume 511.0
As of 3:52 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

incyte corp (ICY) Snapshot

Open
€98.49
Previous Close
€97.41
Day High
€101.77
Day Low
€98.48
52 Week High
04/21/15 - €101.77
52 Week Low
04/29/14 - €32.27
Market Cap
17.6B
Average Volume 10 Days
232.0
EPS TTM
--
Shares Outstanding
173.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INCYTE CORP (ICY)

incyte corp (ICY) Related Businessweek News

No Related Businessweek News Found

incyte corp (ICY) Details

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, as well as INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer. The company’s product pipeline also comprises INCB52793, which is in Phase I/II clinical trial for the treatment of B-lymphoid malignancies; INCB50465 that is in Phase I/II clinical trial for hematology/oncology; and INCB39110+INCB40093, which is in Phase I/II trial for B-lymphoid malignancies. In addition, it is developing epacadostat that is in Phase II clinical trial for metastatic melanoma, as well as in Phase I/II trial for non-small cell lung cancer and various tumor types; and capmatinib, which is in Phase I/II clinical trial for the treatment of solid tumors, as well as in Phase II trial for hepatocellular carcinoma and non-small cell lung cancer. Further, the company is developing INCB54828 that is in Phase I/II clinical trial for the treatment of solid tumors; INCB54329, which is in Phase I/II clinical trial for the treatment of hematology/oncology; and baricitinib that is in Phase III trial for rheumatoid arthritis, as well as in Phase IIb clinical trial for psoriasis, and Phase II trial for diabetic nephropathy. It has a collaboration and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

588 Employees
Last Reported Date: 02/17/15
Founded in 1991

incyte corp (ICY) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $2.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $113.8K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $521.0K
Chief Drug Development Officer and Executive ...
Total Annual Compensation: $403.0K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $365.6K
Compensation as of Fiscal Year 2014.

incyte corp (ICY) Key Developments

Incyte Corporation Establishes New Headquarters of Incyte Europe S.a.r.l in Geneva, Switzerland

Incyte Corporation announced that it will establish the new headquarters of Incyte Europe S.a.r.l in Geneva, Switzerland. The company intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000 sq. ft. facility by mid-2015.

Incyte Corporation Appoints Steven H. Stein as Senior Vice President and Chief Medical Officer

Incyte Corporation announced that Steven H. Stein, MD, has been appointed Senior Vice President and Chief Medical Officer, effective immediately. Dr. Stein was formerly SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be responsible for clinical and medical strategy and operations across Incyte’s extensive oncology portfolio. He will join the executive management team of Incyte, and report to Richard S. Levy, MD, Executive Vice President and Chief Drug Development Officer.

Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study

Eli Lilly and Company and Incyte Corporation announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA). The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional disease-modifying antirheumatic drug (cDMARD). The study met its primary endpoint of an improved ACR20 response rate compared to placebo after 12 weeks of treatment. Part of an extensive Phase 3 program testing baricitinib in more than 3,000 patients at different stages along the RA treatment continuum, the RA-BUILD study enrolled 684 patients with rheumatoid arthritis who previously had an inadequate response to, or were intolerant of, at least one cDMARD and had not received a biologic disease-modifying antirheumatic drug (bDMARD). Patients received either one of two doses of once-daily baricitinib or placebo, in addition to their background therapy. In RA-BUILD, the incidence of treatment-emergent adverse events and serious adverse events with baricitinib treatment, including serious infections, was similar to placebo. There were no opportunistic infections or gastrointestinal perforations in the study. A single case of tuberculosis was reported in a patient receiving baricitinib. The most common adverse events observed were consistent with previous studies of baricitinib in RA. Discontinuation rates due to adverse events were similar between treatment groups. A large majority of patients completing this 6-month trial opted to participate in a long-term extension study. Lilly and Incyte announced top-line results from the first Phase 3 trial of baricitinib, RA-BEACON, which alsomet its primary endpoint, in December 2014 and plan to present detailed data from both RA-BEACON and RA-BUILD at scientific meetings in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICY:GR €101.23 EUR +3.82

ICY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $62.84 USD +1.14
ARIAD Pharmaceuticals Inc $9.27 USD +0.23
BioMarin Pharmaceutical Inc $121.24 USD +1.11
Jazz Pharmaceuticals PLC $186.55 USD -0.195
Vertex Pharmaceuticals Inc $132.20 USD +6.65
View Industry Companies
 

Industry Analysis

ICY

Industry Average

Valuation ICY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit www.incyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.